Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
Source: Cancer Network, June 2018
After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma, according to results from the KEYNOTE-006 trial. The results (abstract 9503) were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1–5 in Chicago.
The KEYNOTE-006 trial included 834 patients with unresectable stage III or IV melanoma. They were randomized to receive one of two schedules of pembrolizumab (556 patients in total), or to ipilimumab (278 patients). The median age was 62 years in both groups, and approximately 35% of the patients had received one prior therapy before entering the trial. About 80% of the cohort was programmed death ligand 1 (PD-L1)–positive.